In fact, from Merck's $1.3 billion deal to GSK's $850 million investment, the "gold content" of Chinese companies' self-developed TCE bispecific antibodies has already been well proven. The new moves ...

Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...

Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney DiseasePlans to Initiate Rare Kidney Diseases Cohort in Early ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

The drug is also in mid-stage clinical trials for primary membranous nephropathy (PMN) and antibody-mediated transplant rejection and is in phase 1 for lupus nephritis. According to the American ...

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated DiseasesNew Program is a ...

(NASDAQ:ARGX – Free Report) had its price target lifted by Piper Sandler from $620.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

1 (TS = (“podocytopathies” OR “minimal change disease” OR “focal segmental glomerulosclerosis” OR “diabetic kidney disease” OR “diabetic nephropathy” OR “lupus nephritis” OR “IgA nephropathy” OR ...

Bayer HealthCare provided support for this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...